Substituted nucleosides, nucleotides and analogs thereof

• US 10,487,104 B2
• Filed: 10/16/2018
• Issued: 11/26/2019
• Est. Priority Date: 12/21/2012
• Status: Active Grant

• Current Assignee: Janssen Biopharma, Inc. (Johnson & Johnson)
• Original Assignee: Janssen Biopharma, Inc. (Johnson & Johnson)
• Inventors: Beigelman, Leonid, Wang, Guangyi, Smith, David Bernard
• Primary Examiner(s): McIntosh, III, Traviss C
• Application Number:
  US16/161,705
• Publication Number:
  US 20190031703A1
• Time in Patent Office: 406 Days
• Field of Search: None
• CPC Class Codes: A61K 31/7076 containing purines, e.g. adenosine, adenylic acid
• CPC Class Codes: A61P 31/14 for RNA viruses
• CPC Class Codes: C07H 19/06 Pyrimidine radicals
• CPC Class Codes: C07H 19/10 with the saccharide radical esterified by phosphoric or polyphosphoric acids
• CPC Class Codes: C07H 19/16 Purine radicals
• CPC Class Codes: C07H 19/173 with 2-deoxyribosyl as the saccharide radical
• CPC Class Codes: C07H 19/20 with the saccharide radical esterified by phosphoric or polyphosphoric acids
• CPC Class Codes: C07H 19/207 the phosphoric or polyphosphoric acids being esterified by a further hydroxylic compound, e.g. flavine adenine dinucleotide or nicotinamide-adenine dinucleotide
• CPC Class Codes: C07H 19/213 containing cyclic phosphate

Abstract

Disclosed herein are nucleotide analogs, methods of synthesizing nucleotide analogs and methods of treating diseases and/or conditions such as a HCV infection with one or more nucleotide analogs.

Claims

1. A compound of Formula (I), or a pharmaceutically acceptable salt thereof, having the structure:

2. The compound of claim 1, wherein R¹ is an unsubstituted C_1-6 alkyl.

3. The compound of claim 1, wherein R¹ is methyl.

4. The compound of claim 1, wherein R¹ is ethynyl.

5. The compound of claim 1, wherein R⁴ is hydrogen.

6. The compound of claim 1, wherein R⁴ is

7. The compound of claim 6, wherein R^5B is an —

O-unsubstituted phenyl; and

R^5A is

8. The compound of claim 6, wherein R^5A is

9. The compound of claim 6, wherein R^5A is

10. The compound of claim 6, wherein R^5A is

11. The compound of claim 10, wherein R^13A and R^13B are each —

O-isopropyl.

12. The compound of claim 1, wherein B¹ is

13. The compound of claim 1, wherein R^6C is ethyl.

14. The compound of claim 1 having a structure selected from the group consisting of:

15. The compound of claim 1 having the structure

16. The compound of claim 1 having the structure

17. The compound of claim 1 having a structure selected from the group consisting of:

18. The compound of claim 1 having a structure selected from the group consisting of:

19. The compound of claim 1 having a structure selected from the group consisting of:

20. The compound of claim 1 having the structure